Classification and therapeutic approaches in autoimmune hemolytic anemia: An update

Expert Review of Hematology

Volumn 4, Issue 6, 2011, Pages 607-618

  Michel, Marc ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

autoimmune hemolytic anemia; cold agglutinins; immune cytopenias; rituximab; warm antibodies

Indexed keywords

AGGLUTININ; ALEMTUZUMAB; ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BENDAMUSTINE; CARDIOLIPIN ANTIBODY; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DANAZOL; DEXAMETHASONE; ECULIZUMAB; ERYTHROCYTE ANTIBODY; FLUDARABINE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; PREDNISONE; RITUXIMAB;

ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTERIAL INFECTION; BLOOD TOXICITY; BONE MARROW BIOPSY; CHRONIC LYMPHATIC LEUKEMIA; CLASSIFICATION ALGORITHM; COLD AGGLUTININ SYNDROME; COMMON VARIABLE IMMUNODEFICIENCY; COMPUTER ASSISTED TOMOGRAPHY; COOMBS TEST; CORTICOSTEROID THERAPY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOELECTROPHORESIS; IMMUNOPHENOTYPING; INFECTION; INFECTION PREVENTION; INFLAMMATORY DISEASE; INFLUENZA; LYMPHOPROLIFERATIVE DISEASE; MULTICENTER STUDY (TOPIC); NEUTROPENIA; PLASMAPHERESIS; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; REVIEW; RISK BENEFIT ANALYSIS; SOLID TUMOR; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; TEMPERATURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; HUMANS;

EID: 81255176800     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.60     Document Type: Review

References (87)

1. Petz LD, Garraty G. Immune Haemolytic Anemias (2nd Edition). Churchill Livingstone, PA, USA (2004).
2. Gerhrs BS, Friedberg RC. Autoimmune hemolytic anemia. Am. J. Hematol. 69, 258-271 (2002). (Pubitemid 34259848)
3. Sokol RJ, Booker DJ, Stamps R. The pathology of autoimmune haemolytic anemia. J. Clin. Pathol. 45, 1047-1052 (1992).
4. Aladjidi N, Leverger G, Leblanc T et al. New insights into childhood autoimmune hemolytic anemia: A French national observational study of 265 children. Haematologica 96(5), 655-663 (2011).
5. Genty I, Michel M, Hermine O et al. [Characteristics of autoimmune hemolytic anemia in adults: Retrospective analysis of 83 cases]. Rev. Med. Int. 23, 901-909 (2002). (Pubitemid 35397865)
6. Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev. 22, 17-31 (2008). (Pubitemid 351179865)
7. Michel M, Chanet V, Dechartres A et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 114(15), 3167-3172 (2009).
8. Barros MMO, Blajchman MA, Bordin JO. Warm autoimmune haemolytic anemia: Recent progress in understanding the immunobiology and treatment. Transfus. Med. Rev. 24, 195-210 (2010).
9. Mqadmi A, Zheng X, Yazdanbakhsh K. CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood 105, 3746-3748 (2005). (Pubitemid 40628226)
10. Semple JW, Freedman J. Autoimmune pathogenesis and autoimmune hemolytic anemia. Sem. Hematol. 42, 122-130 (2005). (Pubitemid 41019440)
11. Michel M. [Characteristics of warm autoimmune hemolytic anemia and Evans syndrome in adults]. Presse Med. 37(9), 1309-1318 (2008).
12. Petz LD. Cold antibody autoimmune haemolytic anemias. Blood Rev. 22, 1-15 (2008). (Pubitemid 351179866)
13. Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Sem. Hematol. 42, 137-144 (2005). (Pubitemid 41019442)
14. Garbe E, Andersohn F, Bronder E et al. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br. J. Haematol. 154, 644-653 (2011).
15. Tsuruta R, Kawamura Y, Inoue T, Kasaoka S, Sadamitsu D, Maekawa T. Corticosteroid therapy for haemolytic anemia and respiratory failure due to Mycoplasma pneumoniae pneumonia. Intern. Med. 41, 229-232 (2002). (Pubitemid 34285444)
16. Mason HM, Ardnt PA. A 13 year-old girl with cold agglutinin syndrome caused by anti-i. J. Pediatr. Hematol. Oncol. 30, 543-545 (2008).
17. Berentsen S, Ulvestad E, Langholm R et al. Primary cold agglutinin disease: A population based clinical study of 86 patients. Haematologica 91, 460-466 (2006).
18. Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood 116 (11), 1831-1838 (2010).
19. Berentsen S, Ulvestad E, Gjertsen BT et al. Rituximab for primary chronic cold agglutinin disease: A prospective study of 37 courses of therapy in 27 patients. Blood 103, 2925-2928 (2004). (Pubitemid 38451661)
20. Schöllkopf C, Kjeldsen L, Weiss Bjerrum O et al. Rituximab in chronic cold agglutinin disease: A prospective study of 20 patients. Leuk. Lymphoma 47, 253-260 (2006). (Pubitemid 43084563)
21. Berentsen S, Randen U, Vågan AM et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood 116(17), 3180-3184 (2010).
22. Crowther M, Chan YT, Garbett IK, Lim W, Vickers MA, Crowther MA. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood doi:10.1182/blood-2011-05-347708 (2011) (Epub ahead of print).
23. Berentsen S, Tjønnfjord GE, Shammas FV et al. No response to cladribine in five patients with chronic cold agglutinin disease. Eur. J. Haematol. 65(1), 88-90 (2000). (Pubitemid 30432031)
24. Petz LD. Cold antibody autoimmune hemolytic anemia. Blood Rev. 22, 1-5 (2008).
25. Hippe E, Jensen KB, Olesen H et al. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood 35, 68-72 (1979).
26. McLeod BC. Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias. Curr. Opin. Hematol. 14, 647-654 (2007). (Pubitemid 47494082)
27. Röth A, Httmann A, Rother RP et al. Long term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 113, 3885 (2009).
28. Salama A, Berghöfer H, Mueller- Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 340, 1515-1517 (1992).
29. Shirey RS, Boyd JS, Parwani AV et al. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: An algorithm for transfusion management. Transfusion 42, 1435-1441(2002).
30. Branch DR, Petz LD. Detecting alloantibodies in patients with autoantibodies. Transfusion 39, 6-10 (1999).
31. Wallhermfechtel MA, Pohl BA, Chaplin H. Alloimmunization in patients with warm autoantibodies. A retrospective study employing three donor alloabsorptions to aid in antibody detection. Transfusion 24, 482-485 (1984). (Pubitemid 15193812)
32. Ruivard M, Tournilhac O, Montel S et al. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: A retrospective case-control study. J. Clin. Apher. 21, 202-206 (2006). (Pubitemid 46591219)
33. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia; results in 73 patients. Am. J. Hematol. 44, 237-242 (1993). (Pubitemid 23328620)
34. Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anemia. Br. J. Haematol. 83, 343-345 (1993).
35. Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol. 84, 122-129 (1990). (Pubitemid 20361936)
36. Coon WW. Splenectomy in the treatment of hemolytic anemia. Arch. Surg. 120, 625-628 (1985). (Pubitemid 15053421)
37. Alpeck G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated diseases. Am. J. Hematol. 61, 98-102 (1999). (Pubitemid 29252385)
38. Vecchio R, Cacciola E, Cacciola RR, Marchese S, Intagliata E. Portal vein thrombosis after laparoscopic and open splenectomy. J. Laparoendosc. Adv. Surg. Tech. A 21(1), 71-75 (2011).
39. Krauth MT, Lechner K, Neugebauer EA, Pabinger I. The postoperative splenic/ portal vein thrombosis after splenectomy and its prevention - an unresolved issue. Haematologica 93(8), 1227-1232 (2008).
40. Hendrick AM. Autoimmune haemolytic anemia - a high risk for thromboembolism? Hematology 8, 53-56 (2003).
41. Bonderman D, Skoro-Sajer N, Jakowitsch J et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 115(16), 2153-2158 (2007). (Pubitemid 46659067)
42. Jaïs X, Ioos V, Jardim C et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 60(12), 1031-1034 (2005). (Pubitemid 41705472)
43. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br. J. Haematol. 141, 149-169 (2008). (Pubitemid 351406218)
44. Quartier P, Brethon B, Philippet P et al. Treatment of childhood autimmune haemolytic anemia with rituximab. Lancet 358, 1511-1513 (2011).
45. Zecca M, Nobili B, Ramenghi U et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101, 3857-3861 (2003). (Pubitemid 36857857)
46. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Evans syndrome. Mayo Clin. Proc. 78, 1340-1346 (2003). (Pubitemid 37337779)
47. Narat S, Gandla J, Hoffbrand AV et al. Rituximab in the treatment of refractory autoimmune cytopenias. Haematologica 90, 1273-1274 (2003).
48. DArena G, Califano C, Annunziata M et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: A retrospective study of 11 adult patients. Eur. J. Hematol. 79, 53-58 (2007). (Pubitemid 47000611)
49. Bussone G, Ribeiro E, Dechartres A et al. Efficacy and safety of rituximab in adults warm antibody autoimmune hemolytic anemia: Retrospective analysis of 27 cases. Am. J. Hematol. 84, 153-157 (2009).
50. Moyo VM, Smith D, Brodsky I et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 100, 704-706 (2002). (Pubitemid 34761141)
51. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory autoimmune haemolytic anemia and autoimmune thrombocytopenic purpura. Br. J. Haematol. 117, 712-715 (2002). (Pubitemid 34539252)
52. Zimmer-Molsberger B, Knauf W, Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anemia. Lancet 350, 1003-1004 (1997). (Pubitemid 27421114)
53. Howard J, Hoffbrand AV, Prentice HG et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br. J. Haematol. 117, 712-715 (2002). (Pubitemid 34539252)
54. Hershko C, Sonnenblick M, Ashkenazi J. Control of steroid-resistant autoimmune haemolytic anemia by cyclosporine. Br. J. Haematol. 76, 436-437 (1990). (Pubitemid 20367859)
55. Emilia G, Messora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br. J. Haematol. 93, 341-347 (1996).
56. Passweg JR, Rabusin M, Musso M et al. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br. J. Haematol. 125, 749-755 (2004). (Pubitemid 38813601)
57. Moyo VM, Smith D, Brodsky I et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 100(2), 704-706 (2002). (Pubitemid 34761141)
58. Willis F, Marsh JCW, Bevan DH et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br. J. Hematol. 114, 891-898 (2011).
59. Kokori SI, Ioannidis JP, Voulgarellis M et al. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am. J. Med. 108, 198-204 (2000). (Pubitemid 30100611)
60. Pullakart V, Ngo M, Iqbal S et al. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anemia at increased risk for venous thromboembolism. Br. J. Haematol. 118, 1166-1169 (2002). (Pubitemid 35025986)
61. Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62(8), 2458-2466 (2010).
62. Patel S, Kramer N, Rosenstein ED. Evolving connective tissue disease influenced by splenectomy: beneath the sword of Dameshek. J. Clin. Rheumatol. 16(6), 280-283 (2010).
63. You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann. Surg. 240(2), 286-292 (2004). (Pubitemid 38963020)
64. Moreno C, Hodgson K, Ferrer G et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 116(23), 4771-4776 (2010).
65. Zent CS, Ding W, Schwager SM et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br. J. Haematol. 141(5), 615-621 (2008). (Pubitemid 351667621)
66. Dearden C, Wade R, Else M et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: A beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 111(4), 1820-1826 (2008). (Pubitemid 351451488)
67. Zanotti R, Frattini F, Ghia P et al. ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. Am. J. Hematol. 85(7), 494-498 (2010).
68. DArena G, Laurenti L, Capalbo S et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am. J. Hematol. 81(8), 598-602 (2006). (Pubitemid 44066170)
69. Gupta N, Kavuru S, Patel D et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 16(10), 2092-2095 (2002). (Pubitemid 35203453)
70. Bowen DA, Call TG, Shanafelt TD et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk. Lymphoma 51(4), 620-627 (2010).
71. Rossignol J, Michallet AS, Oberic et al. Rituximab-cyclophosphamide- dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 25(3), 473-478 (2011).
72. Michallet AS, Rossignol J, Cazin B, Ysebaert L. Rituximab- cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk. Lymphoma 52(7), 1401-1403 (2011).
73. Cortes J, OBrien S, Loscertales J et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 92, 2016-2022 (2001). (Pubitemid 32973308)
74. Hill J, Walsh RM, McHam S, Brody F, Kalaycio M. Laparoscopic splenectomy for autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia: A case series and review of the literature. Am. J. Hematol. 75(3), 134-138 (2004). (Pubitemid 38263820)
75. Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep. 4(1), 47-53 (2009).
76. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 21(3), 511-514 (2007).
77. Gonzalez H, Leblond V, Azar N et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol. Cell Ther. 40(3), 113-118 (1998). (Pubitemid 28280560)
78. Gamberale R, Fernández-Calotti P, Sánchez-Avalos R et al. The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia. Haematologica 91(4), 574-576 (2006).
79. Borthakur G, OBrien S, Wierda WG et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. Br. J. Haematol. 136(6), 800-805 (2007). (Pubitemid 46348418)
80. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2008, 450-456 (2008).
81. Sicherer SH, Winkelstein JA. Primary immunodeficiency diseases in adults. JAMA 279, 58-61 (1998). (Pubitemid 28070553)
82. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol. 92, 34-48 (1999). (Pubitemid 29315984)
83. Michel M, Chanet V, Galicier L et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: Analysis of 21 cases and review of the literature. Medicine 83, 254-263 (2004). (Pubitemid 38955448)
84. Seve P, Bourdillon L, Sarrot-Reynauld F et al. Autoimmune hemolytic anemia and common variable immunodeficiency: A case-control study of 18 patients. Medicine 87, 177-184 (2008). (Pubitemid 351769913)
85. Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J. Autoimmun. 25, 57-62 (2005). (Pubitemid 41008666)
86. Gobert D, Bussel JB, Cunningham-Rundles C et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: A retrospective multicenter study on 33 patients. Br. J. Haematol. doi:10.1111/j.1365-2141.2011.08880.x (2011) (Epub ahead of print).
87. Nugent D, McMillan R, Nichol JI et al. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br. J. Haematol. 146, 585-596 (2009).